Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on developing muscle biology-driven treatments. The company is currently under investigation by Faruqi & Faruqi, LLP for potentially misleading investors about the regulatory timeline for their drug, aficamten. This investigation centers on the absence of a Risk Evaluation and Mitigation Strategy (REMS) in their New Drug Application (NDA), which could delay FDA approval.During a May 6, 2025 earnings call, it was disclosed that C ...